Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012-A00236-37 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective of this study is to compare results for the detection of circulating melanoma cells (CMC) using CellSearch versus EPISPOT (EPithelial ImmunoSPOT) techniques between a group of patients with metastatic melanoma and a group of hospitalized control patients.
The secondary objectives of this study include:
A. To compare the following elements between the two patient groups:
B. To compare the EPISPOT and CellSearch techniques is terms of the following:
C. To re-evaluate the 2-CMC per ml blood threshold
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hospitalized controls | Patients that have been hospitalized at the Nîmes University Hospital and who do not have dermatological cancer. | ||
| Metastatic melanoma | This cohort includes patients with metastatic melanoma. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Presence/absence of at least 2 CMCs per ml blood, both techniques | Presence/absence of at least 2 CMCs per ml blood, using both the Epispot and the CellSearch techniques | Day 1 at 8 am |
| Measure | Description | Time Frame |
|---|---|---|
| CMCs per ml blood, Epispot | The number of CMCs per ml blood as determined by the Epispot technique | Day 1 at 8 am |
| CMCs per ml blood, CellSearch | The number of CMCs per ml blood as determined by the CellSearch technique |
Not provided
Inclusion Criteria:
Inclusion Criteria for patients:
Inclusion Criteria for controls:
Exclusion Criteria:
Exclusion criteria for patients:
Exclusion criteria for controls:
Not provided
Not provided
Not provided
The two cohorts in this study are composed of (1) patients suffering from metastatic melanome and (2) hospitalized patients with no history of cancer.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Laurent Meunier, MD | Centre Hospitalier Universitaire de Nīmes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Montpellier - Hôpital Saint-Eloi | Montpellier | 34295 | France | |||
| CHU de Nîmes - Hôpital Universitaire Carémeau |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31330795 | Result | Cayrefourcq L, De Roeck A, Garcia C, Stoebner PE, Fichel F, Garima F, Perriard F, Daures JP, Meunier L, Alix-Panabieres C. S100-EPISPOT: A New Tool to Detect Viable Circulating Melanoma Cells. Cells. 2019 Jul 20;8(7):755. doi: 10.3390/cells8070755. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008545 | Melanoma |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 1 at 8 am |
| delta CMC | The difference between the number of CMCs per ml blood detected with the CellSearch technique and the Epispot Technique (CellSearch - Epispot) | Day 1 at 8 am |
| % delta CMC | The % difference between the number of CMCs per ml blood detected with the CellSearch technique and the Epispot Technique (CellSearch - Epispot)/CellSearch*100 | Day 1 at 8 am |
| Presence/absence of KI67 antigen markers | Day 1 at 8 am |
| % cells with S100 protein markers | Day 1 at 8 am |
| Nîmes |
| 30029 |
| France |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |